Jinchang Wei

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.

HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.

Journal: Cancer metastasis reviews

Published: April 21, 2026

Features of tumor microenvironment in HER2-positive urothelial carcinoma and its implications for immunotherapy resistance.

Features of tumor microenvironment in HER2-positive urothelial carcinoma and its implications for immunotherapy resistance.

Journal: BMC cancer

Published: April 11, 2026

Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysis.

Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysis.

Journal: International urology and nephrology

Published: February 01, 2026

Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial.

Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial.

Journal: The oncologist

Published: October 07, 2025

Advances in antibody-drug conjugates for urothelial carcinoma treatment.

Advances in antibody-drug conjugates for urothelial carcinoma treatment.

Journal: Cancer biology & medicine

Published: September 23, 2025

MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma.

MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 31, 2025

Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.

Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.

Journal: Urologic oncology

Published: June 30, 2025

A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy.

A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy.

Journal: World journal of urology

Published: November 10, 2024

Showing 1-8 of 8

Last Updated: 09/26/2026